{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    20
  ],
  "modelUsed": "claude-opus-4-5",
  "confidence": 0.7,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_1",
        "affectedSection": "Section 9 - Amendments of the Clinical Investigation Plan",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Protocol establishes amendment procedures requiring joint agreement between Principal Investigators and AION BIOSYSTEMS, INC., with EC/IRB approval before implementation"
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_1",
        "affectedSection": "Section 10 - Deviations from the Clinical Investigation Plan",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Protocol establishes deviation procedures requiring documentation, rationale, and pre-approval before deviations occur"
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_1",
        "reasonText": "Protocol version 2.13 dated 1 May 2024 represents current version; specific amendment rationale not detailed in provided text",
        "category": "Administrative",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_1",
        "reasonText": "Compliance with ISO 14155:2020 requirements for clinical investigation quality assurance and control",
        "category": "Regulatory",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_1",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "9",
        "afterText": "No change to the protocol may be made without the joint agreement of both the Principal Investigators and AION BIOSTYEMS, INC.. Any amendment to the original protocol will be made by AION BIOSTYEMS, INC.. The written amendment must be submitted to ECs/IRBs and the Principal Investigator must await for the approval before implementing the changes, as applicable per local law.",
        "summary": "Established formal amendment approval process requiring joint PI and Sponsor agreement plus EC/IRB approval"
      },
      {
        "id": "change_2",
        "amendmentId": "amend_1",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "9",
        "afterText": "If in the judgment of the ECs/IRBs, the Principal Investigator, and/or AION BIOSTYEMS, INC., the amendment to the protocol substantially changes the study design and/or increases the potential risk to the subject and/or has an impact on the subject's involvement as a study subject, enrolled study subjects will be informed of any changes.",
        "summary": "Added requirement to inform enrolled subjects of substantial protocol changes affecting study design, risk, or subject involvement"
      },
      {
        "id": "change_3",
        "amendmentId": "amend_1",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "10",
        "afterText": "Approvals for deviations will be obtained before the deviation occurs.",
        "summary": "Added requirement for pre-approval of protocol deviations"
      }
    ],
    "summary": {
      "impactCount": 2,
      "reasonCount": 2,
      "changeCount": 3
    }
  }
}